3. During dose escalation only, participants not meeting the above criteria for measurable disease should, at least, have measurable bone marrow plasmacytosis (greater than or equal to [>=] 10%) and/or plasmacytoma (>=1 centimeter [cm] in diameter) detected by physical examination or imaging.